Statement

(Rs. in lakhs)

S.No.	Name of the Company	Ratio of Bulk Drugs production to Formulations		
		1982	1983	1984
1	M/s Abbott Labs.		No bulk drug activity.	
2	M/s Wyeth Labs	1 : 1·4	1 : 1·4	1 : 1·4
3	M/s Geoffrey Manners	1 : 2·5	N.A.	1 : 2·90
4	M/s Warner Hindustan		No bulk drug activity.	
5	M/s Roche Products	1 : 4	1 : 4·07	1 : 4·5
6	M/s Fairdeal Corpn.	1 : 4·51	1 : 4·89	1 : 7 2
7	M/s Smith Kline & French		No bulk drug activity.	
8	M/s Roussels		No bulk drug activity.	
9	M/s Parke Davis	1 : 4·28	1 : 3·669	1 : 4·714
10	M/s Glaro Labs.	1 : 3·4	1 : 3·4	1 :3 7
11	M/s Duphar	N.A.	N.A.	1: 5·94
12	M/s E. Merck	1 : 9·59	1 : 6·48	1 : 4·74
13	M/s Merck Sharp & Dohme (Now Morind)	1 : 2·9	N.A.	1 : 3·1

N.A. : Not available

Excess production of drugs

1539. SHRI NAND KISHORE BHATT: *Will the Minister of* INDUSTRY be pleased to state:

(a) whether it is a fact that most of drug companies are producing formulations much more than licensed capacity with installation of unauthorised plant and machinery as well as producing even without any authority;

(b) whether it is a fact that Warner Hindustan and Abbott do not produce any bulk drug and are engaged in formulation activities;

(c) whether it is also a fact that it has come to Government's notice that these companies have installed unauthorised plant and machinery, overproducing even without any authomitted capacities, overcharged the prices from consumers, manufacturing formulations without any authority and have not implemented the prices fixed for their products; and

(d) if so, what are the details of each company and what steps Government have taken in regard to the working of these companies?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) The requisite information has already been furnished in reply to Rajya Sabha Unstarred Questions No 529 dt. 29.7.1985, Question No. 2272 dt. 19.8.1985 and Question No. 188 dt. 18.11. 1985.

(b) M/s Warner Hindustan do not produce any bulk drug. M/s Abbott Laboratories have very recently reported commencement of the production of bulk drug Pentothal Sodium at their Ankleshwar plant.

(c) and (d) Information regarding M/s Warner Hindustan have been furnished in reply to Rajya Sabha Unstarred Questions No. 1312 dt. 13-5-1985, No. 2304 dt. 19.8-1985 and No. 184 dt. 18-11-1985.

As regards M/s Abbott Labs. Government have not taken a final view on the findings of the technical team which inspected the plant and mach-

inery of the company. The information regarding pricing has been furnished in reply to Rajya Sabha Starred Question No. 367 dt. 19-8-1985.

Disproportionate bulk drugs price declared by multinational drug companies

1540. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that multinational drug companies declared prices for large number of bulk drugs Under Drugs Prices Control Order, 1970 disproportionate to the actual cost of production;

(b) if so, names of drugs for which Government determined fair prices along with declared price under Drugs Price Control Order 1970 and notified price under Drugs Price Control Order 1979 of each;

(c) names of the drugs for which notified prices have been implemented along with for which formulation prices were fixed by Government; and

(d) when and what was the price fixed for each pack, strength of each formulation based on these drugs?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Drugs (Prices Control) Order, 1970 did not contemplate scrutiny of the prices declared price is not known for bulk porters in respect of bulk drugs other than those listed in Schedule-I to the said Order. Therefore, the relation between the cost of production and declared price is not known for bulk drugs other than those in Sechedule-I.

(b) to (d) Do not arise.

Unintended benefit by drug companies

1541. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that drug companies have ammassed huge unintended benefits from formulations based on drugs like Baralgan Ketone, Glybenclamide, Pheniramine, Betamethasone and its salts . Rifampicin Ethambutol· Dextroproxy-phene, Metranidazole. Gentamycin and Doxycycline;

(b) if so, whether any calculation of unintended benefit has been worked out since the introduction of Drugs (Prices Control) Order, 1979.

(c) if so. what are the details thereof;

(d) if not. by when the same will be worked out and placed before the House; and

(e) what is Government's estimate in respect to unintended benefit made by Drug Industry during last five years?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) The prices of Baralgon Ketone, Glybenclamide· Pheniramine Maleate, Betamethasone and its salts and the formulations based on these drugs as enjoyed by M/s. Hoechst (India) Limited and Glaxo Laboratories (India) Limited are those which are allowed by the Delhi High Court. Manufacturers of formulations based on Rifampicin, Metronidazole. Gentamycin have already been issued notices under para 7(2) of Drugs (Prices Control) Order, 1979 and the process of recovery is on in accordance with due procedure of law. The prices of Ethambutol and Dextroproxq-phene have been fixed under Drugs (Prices Control) Order, 1979.

(b) to (d) The process of verification of invoices to determine the difference in accordance with para 7(2) of Drugs (Prices Control) Order, 1979 is on.

(e) No estimates have been drawn by the Government.